Link to Full Article – Armata withdraws its previously filed registration statement on Form S-1 MARINA DEL REY, Calif., Feb. 13, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it has completed the first closing under a recently […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-02-13 02:46:502020-02-14 02:49:01Armata Pharmaceuticals Announces Closing of First Tranche of Recently Executed $25 Million Securities Purchase Agreement with Innoviva, Inc.
Link to Full Article Pharma partner has an exclusive option to a global, royalty bearing licence Cambridge, UK., 13 February 2020: Arecor Ltd (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has signed a further collaboration agreement with a top five pharmaceutical company. The pharmaceutical […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-02-13 02:43:022020-02-14 02:45:51ARECOR SIGNS A NEW FEASIBILITY STUDY AGREEMENT WITH TOP FIVE PHARMA COMPANY
Link to Full Article U.S. RECELL® System product sales of A$4.66M for fiscal second quarter Valencia, Calif., USA, and Melbourne, Australia, 31 January 2020 — AVITA Medical Limited (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, reported financial results for the […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-01-31 02:57:512020-02-04 03:06:47AVITA Medical Reports Second Quarter Fiscal 2020 Financial Results and Company Update
Link to Full Article MARINA DEL REY, Calif. and BRISBANE, Calif., Jan. 28, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata”), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, and Innoviva, Inc. (NASDAQ: INVA) (“Innoviva”), a company with a portfolio of royalties that include respiratory assets partnered with Glaxo Group Limited, today announced that […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-01-28 02:48:422020-02-04 03:07:59Armata Pharmaceuticals and Innoviva Announce $25 Million Strategic Investment to Support Advancement of Armata's Bacteriophage Development Programs
Link to Full Article ARTARMON, NSW, Australia, January 21, 2020 – Saluda Medical Pty Limited (“Saluda Medical”) today announced that data from multiple studies evaluating the company’s Evoke® ECAP-Controlled, Closed-Loop Spinal Cord Stimulation (SCS) System for the treatment of chronic pain will be featured in multiple presentations – including eight oral presentations and award of Best Clinical Abstract – during […]
Link to Full Article Destiny Pharma plc (“Destiny Pharma” or “the Company”) Positive update on the development of new XF‑platform drug formulations Collaboration with MedPharm Ltd. delivers data profiling new XF‑platform drug formulations as potential treatments for dermal and ocular infections New formulations support a growing pipeline alongside lead drug asset, XF-73, currently in Phase […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-01-20 02:18:232020-01-24 02:23:26Update on the development of XF drug formulations
Link to Full Article Cambridge, United Kingdom – 14th January, 2020 – Congenica, a digital health company enabling rapid analysis of complex genomic data to improve disease characterization and diagnosis, today announced the launch of Congenica Neuro™, a new application on its clinical decision support platform that facilitates faster, more accurate and comprehensive characterization and diagnosis of epilepsy and […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-01-14 02:14:502020-01-24 02:17:35Congenica launches new application to enable faster analysis of epilepsy and neurodevelopmental disorders
Link to Full Article Product designed to provide safer, more immediate treatment option for patients London and Cambridge, January 9, 2020 – Hikma Pharmaceuticals PLC (Hikma, Group / LSE: HIK / NASDAQ Dubai: HIK / OTC: HKMPY) (rated Ba1/stable Moody’s and BB+/positive S&P), the multinational generic pharmaceutical company, and Arecor Ltd, the biopharmaceutical company advancing […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-01-09 02:08:282020-01-24 02:10:55HIKMA AND ARECOR ANNOUNCE EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALISE READY-TO-USE MEDICINE USING ARESTAT™ TECHNOLOGY
Link to Full Article Study expected to commence in first half of 2020 Valencia, Calif., USA, and Melbourne, Australia, 30 December 2019 — AVITA Medical Limited (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, announced today that the U.S. Food and […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-12-30 01:22:532020-01-03 01:29:41AVITA Medical Receives U.S. FDA Investigational Device Exemption Approval of Clinical Feasibility Study to Evaluate RECELL System for Vitiligo
Link to Full Article ARTARMON , Australia, Dec. 20, 2019 /PRNewswire/ — Saluda Medical Pty Limited (“Saluda Medical”) today announced The Lancet Neurology journal published results from the U.S. Pivotal Study demonstrating its Evoke® ECAP-Controlled, Closed-Loop Spinal Cord Stimulation (SCS) System provided long-term, statistically superior, and clinically meaningful pain relief for patients with chronic intractable back and leg pain out […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-12-21 02:01:152020-01-03 02:02:15Saluda Medical Results of U.S. Evoke Pivotal Study through 12 Months Published in The Lancet Neurology
Armata Pharmaceuticals Announces Closing of First Tranche of Recently Executed $25 Million Securities Purchase Agreement with Innoviva, Inc.
/in Armata PharmaceuticalsLink to Full Article – Armata withdraws its previously filed registration statement on Form S-1 MARINA DEL REY, Calif., Feb. 13, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it has completed the first closing under a recently […]
ARECOR SIGNS A NEW FEASIBILITY STUDY AGREEMENT WITH TOP FIVE PHARMA COMPANY
/in ArecorLink to Full Article Pharma partner has an exclusive option to a global, royalty bearing licence Cambridge, UK., 13 February 2020: Arecor Ltd (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has signed a further collaboration agreement with a top five pharmaceutical company. The pharmaceutical […]
AVITA Medical Reports Second Quarter Fiscal 2020 Financial Results and Company Update
/in Avita MedicalLink to Full Article U.S. RECELL® System product sales of A$4.66M for fiscal second quarter Valencia, Calif., USA, and Melbourne, Australia, 31 January 2020 — AVITA Medical Limited (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, reported financial results for the […]
Armata Pharmaceuticals and Innoviva Announce $25 Million Strategic Investment to Support Advancement of Armata’s Bacteriophage Development Programs
/in Armata PharmaceuticalsLink to Full Article MARINA DEL REY, Calif. and BRISBANE, Calif., Jan. 28, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata”), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, and Innoviva, Inc. (NASDAQ: INVA) (“Innoviva”), a company with a portfolio of royalties that include respiratory assets partnered with Glaxo Group Limited, today announced that […]
Saluda Medical Highlights Multiple Presentations Featuring Evoke® ECAP-Controlled, Closed-Loop SCS System at NANS Annual Meeting
/in Saluda MedicalLink to Full Article ARTARMON, NSW, Australia, January 21, 2020 – Saluda Medical Pty Limited (“Saluda Medical”) today announced that data from multiple studies evaluating the company’s Evoke® ECAP-Controlled, Closed-Loop Spinal Cord Stimulation (SCS) System for the treatment of chronic pain will be featured in multiple presentations – including eight oral presentations and award of Best Clinical Abstract – during […]
Update on the development of XF drug formulations
/in Destiny PharmaLink to Full Article Destiny Pharma plc (“Destiny Pharma” or “the Company”) Positive update on the development of new XF‑platform drug formulations Collaboration with MedPharm Ltd. delivers data profiling new XF‑platform drug formulations as potential treatments for dermal and ocular infections New formulations support a growing pipeline alongside lead drug asset, XF-73, currently in Phase […]
Congenica launches new application to enable faster analysis of epilepsy and neurodevelopmental disorders
/in CongenicaLink to Full Article Cambridge, United Kingdom – 14th January, 2020 – Congenica, a digital health company enabling rapid analysis of complex genomic data to improve disease characterization and diagnosis, today announced the launch of Congenica Neuro™, a new application on its clinical decision support platform that facilitates faster, more accurate and comprehensive characterization and diagnosis of epilepsy and […]
HIKMA AND ARECOR ANNOUNCE EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALISE READY-TO-USE MEDICINE USING ARESTAT™ TECHNOLOGY
/in ArecorLink to Full Article Product designed to provide safer, more immediate treatment option for patients London and Cambridge, January 9, 2020 – Hikma Pharmaceuticals PLC (Hikma, Group / LSE: HIK / NASDAQ Dubai: HIK / OTC: HKMPY) (rated Ba1/stable Moody’s and BB+/positive S&P), the multinational generic pharmaceutical company, and Arecor Ltd, the biopharmaceutical company advancing […]
AVITA Medical Receives U.S. FDA Investigational Device Exemption Approval of Clinical Feasibility Study to Evaluate RECELL System for Vitiligo
/in Avita MedicalLink to Full Article Study expected to commence in first half of 2020 Valencia, Calif., USA, and Melbourne, Australia, 30 December 2019 — AVITA Medical Limited (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, announced today that the U.S. Food and […]
Saluda Medical Results of U.S. Evoke Pivotal Study through 12 Months Published in The Lancet Neurology
/in Saluda MedicalLink to Full Article ARTARMON , Australia, Dec. 20, 2019 /PRNewswire/ — Saluda Medical Pty Limited (“Saluda Medical”) today announced The Lancet Neurology journal published results from the U.S. Pivotal Study demonstrating its Evoke® ECAP-Controlled, Closed-Loop Spinal Cord Stimulation (SCS) System provided long-term, statistically superior, and clinically meaningful pain relief for patients with chronic intractable back and leg pain out […]